Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
Humacyte Inc (NASDAQ: HUMA) closed the day trading at $1.23 down -5.38% from the previous closing price of $1.3. In other words, the price has decreased by -$5.38 from its previous closing price. On the day, 3.95 million shares were traded. HUMA stock price reached its highest trading level at $1.31 during the session, while it also had its lowest trading level at $1.23.
Ratios:
For a better understanding of HUMA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.90 and its Current Ratio is at 1.62.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on August 27, 2025, initiated with a Overweight rating and assigned the stock a target price of $3.50.
H.C. Wainwright reiterated its Buy rating for the stock on December 20, 2024, while the target price for the stock was revised from $12 to $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 19 ’25 when Dougan Brady W sold 1,100,000 shares for $1.63 per share. The transaction valued at 1,793,000 led to the insider holds 591,685 shares of the business.
Dougan Brady W sold 549,360 shares of HUMA for $1,005,329 on Aug 18 ’25. The Director now owns 1,691,685 shares after completing the transaction at $1.83 per share. On Aug 20 ’25, another insider, Dougan Brady W, who serves as the Director of the company, sold 591,685 shares for $1.58 each. As a result, the insider received 934,862 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUMA now has a Market Capitalization of 230343744 and an Enterprise Value of 261826720. For the stock, the TTM Price-to-Sale (P/S) ratio is 146.71. Its current Enterprise Value per Revenue stands at 166.662 whereas that against EBITDA is -2.69.
Stock Price History:
The Beta on a monthly basis for HUMA is 1.90, which has changed by -0.7081851 over the last 52 weeks, in comparison to a change of 0.13506866 over the same period for the S&P500. Over the past 52 weeks, HUMA has reached a high of $6.77, while it has fallen to a 52-week low of $1.09. The 50-Day Moving Average of the stock is -19.55%, while the 200-Day Moving Average is calculated to be -37.83%.
Shares Statistics:
Over the past 3-months, HUMA traded about 5.20M shares per day on average, while over the past 10 days, HUMA traded about 3752250 shares per day. A total of 158.84M shares are outstanding, with a floating share count of 158.02M. Insiders hold about 15.62% of the company’s shares, while institutions hold 24.69% stake in the company. Shares short for HUMA as of 1763078400 were 33414650 with a Short Ratio of 6.42, compared to 1760486400 on 27220587. Therefore, it implies a Short% of Shares Outstanding of 33414650 and a Short% of Float of 20.02.
Earnings Estimates
The market rating of Humacyte Inc (HUMA) is currently shaped by the ongoing analysis conducted by 3.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.12, with high estimates of -$0.12 and low estimates of -$0.12.
Analysts are recommending an EPS of between -$0.18 and -$0.58 for the fiscal current year, implying an average EPS of -$0.38. EPS for the following year is -$0.53, with 4.0 analysts recommending between -$0.46 and -$0.67.
Revenue Estimates
For the next quarter, 6 analysts are estimating revenue of $3.94M. There is a high estimate of $5.85M for the next quarter, whereas the lowest estimate is $2.4M.
Based on 6 analysts’ estimates, the company’s revenue will be $23.65M in the next fiscal year. The high estimate is $44.63M and the low estimate is $11.03M.
